Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
646
datasets available to search
ShareScore release 0.9.0
Dataset results
646 results for “Clinical data”
Data from: First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.
Data from: Aldosterone reduction rate after saline infusion may be a novel clinical prediction of determining subtypes of primary aldosteronism
<p><span><span><span><span><span><span><span><span><span><span><span><b>Objective</b>Accurate assessment of the localization of aldosterone-producing adenomas (APAs) is essential for the treatment of primary aldosteronism (PA). Although adrenal venous sampling (AVS) is the standard method of reference for subtype diagnosis in PA, controversy exists concerning the criteria for interpretation. This study aimed to determine better indicators that can reliably predict subtypes of PA. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Method</b>Retrospective analysis in single-cohort including 209 patients with PA who were subjected to AVS. 82 patients whose plasma aldosterone concentrations (PAC) were normalized after surgery were histopathologically or genetically diagnosed with APA. The accuracy of image findings was compared to AVS results. Receiver operating characteristic (ROC) curve analysis between the operated and no apparent laterality groups was performed using AVS parameters and loading test for diagnosis of PA. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Result </b>The agreement between image findings and AVS results was 56.3%. ROC curve analysis revealed that lateralization index (LI) after ACTH stimulation cutoff value was 2.40, with 98.8% sensitivity and 97.1% specificity. The contralateral suppression index (CSI) cutoff value was 1.19, with 98.0% sensitivity and 93.9% specificity. All patients over the LI and CSI cutoff values exhibited unilateral subtypes. Among the loading test, <span><span>the best classification accuracy was achieved using the </span></span>PAC reduction rate after saline infusion<span><span>test (SIT) >33.8%, which yielded 87.2% sensitivity or PAC after SIT <87.9 pg/mL 86.2% specificity for predicting bilateral PA. </span></span></span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Conclusion</b>The combined criterion of the PAC reduction rate and PAC after SIT may determine a subset of patients with APA who should be performed AVS for validation. </span></span></span></span></span></span></span></span></span></span></span></p> <p><br> </p>
Data from: Non-clinical safety assessment of CFZ533, a Fc-silent anti-CD40 antibody, in Cynomolgus monkeys
CFZ533 is a pathway blocking, non-depleting anti-CD40 antibody that is in clinical development for inhibition of transplant organ rejection and therapy for autoimmune diseases. A 26-week GLP toxicity study in sexually mature Cynomolgus monkeys was conducted in order to support chronic application of CFZ533. CFZ533 was subcutaneously administered at doses up to 150 mg/kg/week and was safe and generally well tolerated. CFZ533 showed no adverse effects for cardiovascular, respiratory and neurobehavioral endpoints, and no changes were observed for blood lymphocyte and platelet counts or blood coagulation markers. In line with the non-depleting nature of CFZ533, CD20+ B cells in the blood were only marginally reduced. A complete suppression of germinal center (GC) development in lymph nodes and spleen was the most prominent result of post-mortem histological investigations. This was corroborated by an abrogated T-dependent antibody response (TDAR) to the antigen Keyhole Limpet Hemocyanin (KLH) as well as an absence of anti-drug antibodies (ADAs) in the absence of B cell depletion as seen with immunophenotyping and histology. When serum levels of CFZ533 in recovery animals dropped levels necessary for full CD40 occupancy on B cells, all animals were able to mount a TDAR to KLH. All histological changes also reverted to normal appearance after recovery. In summary, CFZ533 was shown to be well tolerated and safe in the 26-week toxicity study with a distinct pharmacodynamic profile in histology and immune function.
Clinical data of patients and values of antibodies in the IgM, IgA and IgG classess against Mycoplasma pneumoniae
<p><span>Data on <em>Mycoplasma pneumoniae</em> infections during last years are very limited. In this manuscript, we presented the assessment of the seroprevalence of antibodies against <em>Mycoplasma pneumoniae</em> in the numerous group of patients, as well as clinical aspects of the differential diagnostics of respiratory tract infections.</span></p>
Data for "Joint Clinical and Molecular Subtyping of COPD with Variational Autoencoders"
<p>Data for paper "Data for "Joint Clinical and Molecular Subtyping of COPD with Variational Autoencoders", Maiorino et al.</p> <p>The associated code repository is at<a href="https://github.com/reemagit/joint_subtyping_vae"> https://github.com/reemagit/joint_subtyping_vae</a></p>
Data for multi-dimensional characterization of cellular states in ovarian cancer reveals clinically relevant immunological subtypes and therapeutic vulnerabilities
<p>The data for figures</p>
Data from: Clinical scores before and after multi-nodal DBS
<p><em>Background</em></p> <p>Mixed and complex movement disorders represent significant challenges for surgical treatment. These disease states are likely the result of combined or complex network pathologies affecting multiple pathways<sup>1-4</sup>. Until recently, attempts to treat complex movement disorders with deep brain stimulation (DBS) have primarily focused on stimulating a single deep target to address patients' most severe symptoms<sup>5-14</sup>. However, a multi-nodal targeting approach for DBS by simultaneously stimulating more than one pair of homologous nuclei could be a more effective treatment strategy. Here, we present the technique and initial case series of utilizing multi-nodal stimulation for mixed and complex movement disorders.</p> <p><em>Methods</em></p> <p>An initial cohort of fifteen mixed and complex movement disorder patients presenting to Stanford University underwent a multi-nodal stimulation approach. In these patients, the multiple (i.e. > 2) simultaneous deep targets were implanted through only 2 burr holes and connected to a single 32-channel pulse generator.</p> <p><em>Results</em></p> <p>There were no intra- or post-operative complications. With the addition of multi-nodal stimulation, complex PD patients demonstrated a significant reduction in Unified Parkinson's Disease Rating Scale (p = 0.0039) and complex tremor patients demonstrated a significant reduction in Clinical Rating Scale for Tremor (p = 0.0312).</p> <p><em>Conclusion</em></p> <p>We present the largest initial case series demonstrating the safety, feasibility, and added efficacy of single system multi-nodal DBS for treating mixed and complex movement disorders. This approach is safe, provides additional benefit, and warrants further investigation for treating mixed and complex movement disorders.</p>
Clinical data from cervical precancerous lesions, Hospital de la Mujer
<p>Se muestran los datos de mujeres con lesiones precursoras cervicales del Hospital de la Mujer en CDMX</p>
Processed gene and clinical data
<p>The processed cancer dataset mentioned in the paper "Cox-Sage: Enhancing Cox proportional hazards model with interpretable graph neural networks for cancer prognosis," which is currently under review in Briefings in Bioinformatics. The gene expression data and clinical data of seven cancer types downloaded from TCGA (https://portal.gdc.cancer.gov/) were processed to retain only protein-coding genes. A patient similarity graph was constructed based on the similarity of clinical data. The data for each type of cancer consists of a `gene_expression.csv`, a `clinical.csv`, and an `adj_list.pkl`. In addition, the `prognostic_genes.zip` file contains the hazards contour plot of all prognostic genes identified in the study. And the `all_benchmarks_prediction_results.zip` file contains the hazards prediction results of all benchmarks that being reproduced.</p>
Data from: Clinical correlation of multiple sclerosis immunopathological subtypes
<p><b>Objective:</b> To compare clinical characteristics across immunopathological subtypes of patients with multiple sclerosis.</p> <p><b>Methods:</b> Immunopathological subtyping was performed on specimens from 547 patients with biopsy and/or autopsy confirmed CNS demyelination.</p> <p><b>Results: </b>The frequency of immunopathological subtypes were pattern I (23%), II (56%), and III (22%). Immunopatterns were similar in terms of age at autopsy/biopsy (median age 41 years, range 4-83 years, p=0.16) and proportion female (54%, p=0.71). Median follow-up after symptom onset was 2.3 years (range 0-38y). In addition to being overrepresented among autopsy cases (45% vs. 19% in biopsy cohort, p<0.001), index attack-related disability was higher in pattern III vs. pattern II (median EDSS 4 vs. 3, p=0.02). Monophasic clinical course was more common in patients with pattern III than pattern I or II (59% vs. 33% vs. 32%, p<0.001). Similarly, patients with pattern III pathology were likely to have progressive disease compared to patients with patterns I or II, when followed for ≥5 years (24% overall, p=0.49), with no differences in long-term survival, despite a more fulminant attack presentation.</p> <p><b>Conclusion:</b> All three immunopatterns can be detected in active lesions, although they are found less frequently later into the disease due to the lower number of active lesions. Pattern III is associated with a more fulminant initial attack than either pattern I or II. Biopsied patients appear to have similar long-term outcomes irrespective of their immunopatterns. Progressive disease is less associated with the initial immunopattern and suggests convergence into a final common pathway related to the chronically denuded axon.</p>
Data from: Clinical presentation and management of SMART syndrome
<div class="WordSection1"> <p><span>Stroke-like migraine attacks after radiation therapy (SMART) syndrome represents a rare but serious condition manifesting years after cranial radiation therapy (RT). Characterized by migraine-type headaches, stroke-like deficits and/or seizures and MR imaging abnormalities, including cortical gyriform enhancement in irradiated brain regions, SMART remains diagnostically and therapeutically challenging. Distinction from tumor progression is difficult and treatment options are limited. Although frequently reversible, SMART episodes can recur and effectuate persistent neurologic and/or imaging sequelae.</span></p> </div>
Radiomics metrics combined with clinical data in the surgical management of early-stage (cT1-T2 N0) of tongue squamous cell carcinomas: a preliminary study
<p>We uploaded the clinical and the hematological parameters of enrolled patients in the study "Radiomics metrics combined with clinical data in the surgical management of early-stage (cT1-T2 N0) of tongue squamous cell carcinomas: a preliminary study" accepted on Biology journal.</p> <p>Clinical and hematological parameters include: age; gender; DOI, NLR; PLR; LMR; SIRI; SII; T stage; grading; metastatic lymph nodes; perineural infiltration; vascular infiltration.</p> <p> </p>
Demographic data, anthropometric measurements, and clinical parameters
<p>Demographic data, anthropometric measurements, and clinical parameters</p>
Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study
<p><strong>Purpose:</strong> Infection by carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality.</p> <p><strong>Methods:</strong><strong> </strong>This retrospective cohort study included patients with pneumonia caused by CRKP for three years. The primary outcomes were 7-day bacterial eradication rate and 14- and 28-day all-cause mortality. The secondary outcome was incidence of acute kidney injury.</p> <p><strong>Results:</strong><strong> </strong>Seventy-three patients were included in this study, 29 in the<strong> </strong>polymyxin B-based combination therapy group and 44 in tigecycline-based combination therapy group. There were no significant differences between the two groups in terms of the 7-day bacterial eradication rate (31.0% vs 20.5%, <em>P</em>=0.409), the 14-day all-cause mortality (37.9% vs 22.7%, <em>P</em>=0.160), and the incidence of acute kidney injury (14.3% vs 6.8%, <em>P</em>=0.526). The 28-day all-cause mortality in the polymyxin B-based therapy group was higher than in the tigecycline-based group (75.9% vs 45.5%, <em>P</em>=0.010). Binary logistic regression analysis revealed that male and previous use of carbapenems were independent factors associated with 28-day all-cause mortality for patients treated with polymyxin B (<em>P</em><0.05).</p> <p><strong>Conclusions:</strong><strong> </strong>Polymyxin B-based combination therapy at the standard dose should be used with caution for patients with CRKP-induced pneumonia, especially for men who used carbapenems prior to CRKP detection.</p>
Dataset for Spence et al., "Patient consent to publication and data sharing in industry and NIH-funded clinical trials" (Trials 2018 19:269).
<p>Dataset for our journal publication (Spence et al. 2018 <a href="https://doi.org/10.1186/s13063-018-2651-2">https://doi.org/10.1186/s13063-018-2651-2</a>). This dataset contains</p> <ul> <li>Informed consent forms (ICFs) for 98 industry-funded clinical trials</li> <li>Informed consent forms (ICFs) for 46 NIH-funded clinical trials</li> <li>Our extraction datasheet</li> </ul>
States of genome assembly supporting data for complete genome assembly of clinical multidrug resistant Bacteroides fragilis isolates enables comprehensive identification of antimicrobial resistance genes and plasmids.
<p>Assemblies for each isolate and assembly stage is in .gfa and .fasta format.</p> <p>the best SPAdes assembly is also included in the .zip files.</p> <p>1) Unicycler with illumina data and Nanopore data from the first sequencing run, filtered with FiltLong.<br> 2) Unicycler with illumina data and Nanopore data from the first sequencing run, filtered with FiltLong and error corrected with Canu<br> 3) Unicycler with illumina data and Nanopore data from the first and second sequencing run, filtered with FiltLong.<br> 4) manual finshing of assembly 3. <br> Methods are described in the paper and at the github repository (https://github.com/thsyd/bfassembly)</p> <p> </p>
Data From: ChatGPT versus expert feedback on clinical reasoning questions and their effect on learning: a randomized controlled trial
<p>Dataset Info</p> <p><strong>1) Immediate Test</strong><br>- The first row of the dataset identifies the columns.<br>- Column A represents the participants’ iDs.<br>- Column B represents the participants’ assigned group [0: Control (ExpertFeedback) 1: Intervention (ChatGPTFeedback)].<br>- Column C represents the genders of the participants (1: Female, 2: Male).<br>- Column D represents the first-year repetition status of the participants. (0: No, 1: Yes)<br>- Column E to H represent the scores in four different uncomplicated urinary tract infection (UTI) Key-Features Questions Items separately. <br>- Column I represents the total scores in uncomplicated UTI Key-Features Questions Items. <br>- Column J to M represent the scores in four different complicated UTI Key-Features Questions Items separately. <br>- Column N represents the total scores in complicated UTI Key-Features Questions Items. <br>- Column O to R represent the scores in four different pyelonephritis Key-Features Questions Items separately. <br>- Column S represents the total scores in pyelonephritis Key-Features Questions Items. <br>- Column T represents the total scores in immediate test. </p> <p><strong>2) Delayed Test</strong><br>- The first row of the dataset identifies the columns.<br>- Column A represents the participants iDs.<br>- Column B represents the participants’ assigned group [0: Control (ExpertFeedback) 1: Intervention (ChatGPTFeedback)].<br>- Column C represents the genders of the participants (1: Female, 2: Male).<br>- Column D represents the first-year repetition status of the participants. (0: No, 1: Yes)<br>- Column E to H represent the scores in four different uncomplicated urinary tract infection (UTI) Key-Features Questions Items separately. <br>- Column I represents the total scores in uncomplicated UTI Key-Features Questions Items. <br>- Column J to M represent the scores in four different complicated UTI Key-Features Questions Items separately. <br>- Column N represents the total scores in complicated UTI Key-Features Questions Items. <br>- Column O to R represent the scores in four different pyelonephritis Key-Features Questions Items separately. <br>- Column S represents the total scores in pyelonephritis Key-Features Questions Items. <br>- Column T represents the total scores in delayed test. </p> <p><strong>3) Pre-Intervention Survey on Critical Approach to AI</strong><br>- The first row of the dataset identifies the columns.<br>- Column A represents the participants iDs.<br>- Column B represents the participants’ assigned group [0: Control (ExpertFeedback) 1: Intervention (ChatGPTFeedback)].<br>- Column C represents the genders of the participants (1: Female, 2: Male).<br>- Column D represents the first-year repetition status of the participants (0: No, 1: Yes).<br>- Column E to J represent the responses of the participants to survey questions before the intervention. Each column is evaluated on a scale from 1 to 7. As it progresses from 1 to 7, the agreement status of participants to survey questions increases. (1: No agreement at all, 7: completely agree)</p> <p><strong>4) Post-Intervention Survey on Critical Approach to AI</strong><br>- The first row of the dataset identifies the columns.<br>- Column A represents the participants iDs.<br>- Column B represents the participants’ assigned group [0: Control (ExpertFeedback) 1: Intervention (ChatGPTFeedback)].<br>- Column C represents the genders of the participants (1: Female, 2: Male).<br>- Column D represents the first-year repetition status of the participants (0: No, 1: Yes).<br>- Column E to J represent the evaluation of the participants to survey questions after intervention. Each column is evaluated on a scale from 1 to 7. As it progresses from 1 to 7, the agreement status of participants to survey questions increases. (1: No agreement at all, 7: completely agree)</p>
The usage of transcriptomics datasets as sources of Real-World Data for clinical trialling -- Supplementary Data
Open the record for dataset details and reuse information.
Data from: Sustainability of professionals' adherence to clinical practice guidelines in medical care: a systematic review
Objectives: To evaluate (1) the state of the art in sustainability research and (2) the outcomes of professionals' adherence to guideline recommendations in medical practice. Design: Systematic review. Data sources: Searches were conducted until August 2015 in MEDLINE, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and the Guidelines International Network (GIN) library. A snowball strategy, in which reference sections of other reviews and of included papers were searched, was used to identify additional papers. Eligibility criteria: Studies needed to be focused on sustainability and on professionals' adherence to clinical practice guidelines in medical care. Studies had to include at least 2 measurements: 1 before (PRE) or immediately after implementation (EARLY POST) and 1 measurement longer than 1 year after active implementation (LATE POST). Results: The search retrieved 4219 items, of which 14 studies met the inclusion criteria, involving 18 sustainability evaluations. The mean timeframe between the end of active implementation and the sustainability evaluation was 2.6 years (minimum 1.5–maximum 7.0). The studies were heterogeneous with respect to their methodology. Sustainability was considered to be successful if performance in terms of professionals' adherence was fully maintained in the late postimplementation phase. Long-term sustainability of professionals' adherence was reported in 7 out of 18 evaluations, adherence was not sustained in 6 evaluations, 4 evaluations showed mixed sustainability results and in 1 evaluation it was unclear whether the professional adherence was sustained. Conclusions: (2) Professionals' adherence to a clinical practice guideline in medical care decreased after more than 1 year after implementation in about half of the cases. (1) Owing to the limited number of studies, the absence of a uniform definition, the high risk of bias, and the mixed results of studies, no firm conclusion about the sustainability of professionals' adherence to guidelines in medical practice can be drawn.
Clinical Trial Transparency and Data-Sharing Among Bio-Pharmaceutical Companies and the Role of Company Size, Location, and Product Type: A Cross-Sectional Descriptive Analysis
<p><b>Objective</b>: To examine company characteristics associated with better transparency and to apply a tool used to measure and improve clinical trial transparency among large companies and drugs, to smaller companies and biologics.</p> <p><b>Design</b>: Cross-sectional descriptive analysis.</p> <p><b>Setting and participants. </b>Novel drugs and biologics FDA approved in 2016 and 2017, and their company sponsors.</p> <p>Using established Good Pharma Scorecard (GPS) measures, companies and products were evaluated on their clinical trial registration, results dissemination, and FDA Amendments Act (FDAAA) implementation; Companies were ranked using these measures and a multi-component data sharing measure. Associations between company transparency scores with company size (large vs non-large), location (US vs non-US), and sponsored product type (drug vs biologic) were also examined. 26% of products (16/62) had publicly available results for all clinical trials supporting their FDA approval and 67% (39/58) had public results for trials in patients by 6 months after their FDA approval; 58% (32/55) were FDAAA compliant. Large companies were significantly more transparent than non-large companies (overall median transparency score of 95% [IQR 91-100] vs 59% [IQR 41-70], p<0.001), attributable to higher FDAAA compliance (median of 100% [IQR 88-100] vs 57% [0-100], p=0.01) and better data sharing (median of 100% [IQR 80-100] vs 20% [IQR 20-40], p<0.01). No significant differences were observed by company location or product type. It was feasible to apply the GPS transparency measures and ranking tool to non-large companies and biologics. Large companies are significantly more transparent than non-large companies, driven by better data sharing procedures and implementation of FDAAA trial reporting requirements. Greater research transparency is needed, particularly among non-large companies, to maximize the benefits of research for patient care and scientific innovation. </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.